JP2016506916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506916A5 JP2016506916A5 JP2015553788A JP2015553788A JP2016506916A5 JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5 JP 2015553788 A JP2015553788 A JP 2015553788A JP 2015553788 A JP2015553788 A JP 2015553788A JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- cycloalkyl
- group
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| US61/753,066 | 2013-01-16 | ||
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506916A JP2016506916A (ja) | 2016-03-07 |
| JP2016506916A5 true JP2016506916A5 (enExample) | 2017-01-26 |
| JP6347793B2 JP6347793B2 (ja) | 2018-06-27 |
Family
ID=51165292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553788A Active JP6347793B2 (ja) | 2013-01-16 | 2014-01-15 | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (enExample) |
| EP (2) | EP2945940B1 (enExample) |
| JP (1) | JP6347793B2 (enExample) |
| KR (2) | KR102318204B1 (enExample) |
| CN (3) | CN105246882A (enExample) |
| AU (1) | AU2014207716B2 (enExample) |
| CA (1) | CA2897055C (enExample) |
| ES (1) | ES2819232T3 (enExample) |
| HK (1) | HK1219734A1 (enExample) |
| NZ (1) | NZ709635A (enExample) |
| SG (1) | SG11201505525UA (enExample) |
| WO (1) | WO2014113413A1 (enExample) |
| ZA (1) | ZA201504902B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1219734A1 (zh) * | 2013-01-16 | 2017-04-13 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl抑制劑和使用所述抑制劑的治療方法 |
| BR112016017564A8 (pt) | 2014-01-28 | 2018-04-17 | Buck Inst Res Aging | métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| US10071087B2 (en) | 2014-07-22 | 2018-09-11 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| EP3253387A4 (en) * | 2015-02-06 | 2018-12-19 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditons |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| RU2726367C2 (ru) | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| WO2019133988A1 (en) | 2017-12-30 | 2019-07-04 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| KR20200108298A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| JP7385284B2 (ja) * | 2018-01-22 | 2023-11-22 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー | 癌処置のためのｂｃｌ－２タンパク質分解剤 |
| JP2021521138A (ja) | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Ｂｃｌ−２阻害剤 |
| CN110662752B (zh) | 2018-04-30 | 2022-01-14 | 尤尼蒂生物技术公司 | 用于临床管理由衰老细胞引起或介导的病症以及治疗癌症的Bcl家族拮抗剂磷杂环化合物 |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| EP3829593A4 (en) * | 2018-07-31 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof |
| US11478469B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| KR20200139139A (ko) | 2018-07-31 | 2020-12-11 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| US11872237B2 (en) | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| EP3906235B1 (en) * | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| US11370807B2 (en) | 2019-01-04 | 2022-06-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Process for preparing sulfonamide compounds |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| JP2021535129A (ja) * | 2019-07-31 | 2021-12-16 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害剤及び化学療法剤の組み合わせ製品、並びに疾患の予防及び／又は治療におけるその使用 |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| US12514863B2 (en) | 2019-12-04 | 2026-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| WO2021119439A1 (en) * | 2019-12-11 | 2021-06-17 | The Regents Of The University Of Michigan | Compositions and methods for systemic delivery of bcl-2 and bcl-xl antagonists |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| WO2021204060A1 (en) * | 2020-04-10 | 2021-10-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Combinations of bcl-2/bcl-xl inhibitors and related uses |
| BR112022019525A2 (pt) | 2020-04-15 | 2023-11-14 | Beigene Ltd | Composto, composição farmacêutica e método para tratar doenças apoptóticas desreguladas |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| WO2022008464A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2022012481A1 (en) * | 2020-07-13 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts |
| WO2022022706A1 (en) * | 2020-07-31 | 2022-02-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating lung diseases |
| EP4244231A4 (en) * | 2020-11-10 | 2024-08-21 | Unity Biotechnology, Inc. | CRYSTALLINE SOLID MEGLUMIN SALT INHIBITOR OF BCL AND METHOD OF PREPARING AND USING THE SAME |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| US12454674B2 (en) | 2020-12-04 | 2025-10-28 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| US20250099440A1 (en) | 2021-08-02 | 2025-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| EP4565236A1 (en) * | 2022-08-02 | 2025-06-11 | Beijing Neox Biotech Limited | Bcl-xl degrading compounds |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| US7842681B2 (en) * | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
| HRP20120577T1 (hr) | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences S.R.L. | 3,4-diarilpirazoli kao inhibitori proteinskih kinaza |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| HK1219734A1 (zh) * | 2013-01-16 | 2017-04-13 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl抑制劑和使用所述抑制劑的治療方法 |
-
2014
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506916A5 (enExample) | ||
| JP2014507421A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2019529518A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2016513737A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2021502345A (ja) | 抗がん剤 | |
| JP2013507415A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| JP2019509986A (ja) | トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 | |
| JP2016515628A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| JP2016531871A5 (enExample) | ||
| CN110248662A (zh) | 一种治疗前列腺癌的组合、药物组合物及治疗方法 | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2020534346A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2015502367A5 (enExample) |